New Two-Pronged attack tested against tough head and neck cancers
NCT ID NCT07346196
Summary
This study is testing if adding a new drug called fianlimab to a standard immunotherapy (cemiplimab) and chemotherapy works better for shrinking tumors in adults with advanced HPV-positive head and neck cancer. It will compare the two-drug combo to the single drug to see which leads to better response rates and longer survival. The goal is to find a more effective treatment to control this serious cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.